That work has blossomed into a $13 million NIH-funded collaboration among several universities aimed at understanding how the immune system is tricked by chronic infections such as HIV/AIDS and hepatitis C. In the journal Nature, scientists described what appears to be an attractive target for HIV therapy: the molecule known as programmed death-1.